Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Yoshiaki NakamuraNobumasa MizunoYu SunakawaJean-Luc CanonMatthew D GalskyErika Paige HamiltonHidetoshi HayashiGuy JerusalemSeung Tae KimKeun-Wook LeeLionel Aurelien Kankeu FonkouaBradley J MonkDanny NguyenDo Youn OhAlicia F C OkinesDavid M O'MalleyPaula PohlmannMartin ReckSang Joon ShinKazuki SudoShunji TakahashiCedric Van MarckeEvan Y YuRoman GroisbergJorge RamosSherry TanThomas Eldridge StinchcombeTanios S Bekaii-SaabPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC.
Keyphrases
- epidermal growth factor receptor
- phase ii
- tyrosine kinase
- advanced non small cell lung cancer
- clinical trial
- open label
- endothelial cells
- papillary thyroid
- squamous cell carcinoma
- small cell lung cancer
- randomized controlled trial
- phase iii
- newly diagnosed
- pluripotent stem cells
- lymph node metastasis
- metastatic breast cancer